1. Home
  2. UFI vs OPTN Comparison

UFI vs OPTN Comparison

Compare UFI & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UFI
  • OPTN
  • Stock Information
  • Founded
  • UFI 1969
  • OPTN 2010
  • Country
  • UFI United States
  • OPTN United States
  • Employees
  • UFI N/A
  • OPTN N/A
  • Industry
  • UFI Textiles
  • OPTN Biotechnology: Pharmaceutical Preparations
  • Sector
  • UFI Consumer Discretionary
  • OPTN Health Care
  • Exchange
  • UFI Nasdaq
  • OPTN Nasdaq
  • Market Cap
  • UFI N/A
  • OPTN 78.4M
  • IPO Year
  • UFI N/A
  • OPTN 2017
  • Fundamental
  • Price
  • UFI $5.70
  • OPTN $0.44
  • Analyst Decision
  • UFI
  • OPTN Strong Buy
  • Analyst Count
  • UFI 0
  • OPTN 3
  • Target Price
  • UFI N/A
  • OPTN $3.00
  • AVG Volume (30 Days)
  • UFI 58.2K
  • OPTN 840.6K
  • Earning Date
  • UFI 01-29-2025
  • OPTN 11-12-2024
  • Dividend Yield
  • UFI N/A
  • OPTN N/A
  • EPS Growth
  • UFI N/A
  • OPTN N/A
  • EPS
  • UFI N/A
  • OPTN N/A
  • Revenue
  • UFI $590,737,000.00
  • OPTN $75,672,000.00
  • Revenue This Year
  • UFI $11.45
  • OPTN $13.42
  • Revenue Next Year
  • UFI $6.84
  • OPTN $52.99
  • P/E Ratio
  • UFI N/A
  • OPTN N/A
  • Revenue Growth
  • UFI 1.35
  • OPTN 5.13
  • 52 Week Low
  • UFI $5.41
  • OPTN $0.32
  • 52 Week High
  • UFI $7.91
  • OPTN $2.10
  • Technical
  • Relative Strength Index (RSI)
  • UFI 48.35
  • OPTN 34.94
  • Support Level
  • UFI $5.50
  • OPTN $0.34
  • Resistance Level
  • UFI $5.87
  • OPTN $0.42
  • Average True Range (ATR)
  • UFI 0.13
  • OPTN 0.05
  • MACD
  • UFI 0.05
  • OPTN -0.00
  • Stochastic Oscillator
  • UFI 48.84
  • OPTN 21.32

About OPTN OptiNose Inc.

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Share on Social Networks: